Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
« Previous Article | Table of Contents | Next Article »
Circulation. 1995;92:290-295

This Article
Right arrow Abstract Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ferrières, J.
Right arrow Articles by Davignon, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ferrières, J.
Right arrow Articles by Davignon, J.

(Circulation. 1995;92:290-295.)
© 1995 American Heart Association, Inc.

Articles

Coronary Artery Disease in Heterozygous Familial Hypercholesterolemia Patients With the Same LDL Receptor Gene Mutation

J. Ferrières, MD, MSc; J. Lambert, PhD; S. Lussier-Cacan, PhD; J. Davignon, MD, MSc

From Département de médecine sociale et préventive, Faculté de Médecine, Université de Montréal, Montreal, Quebec, Canada (J.F., J.L.), and the Hyperlipidemia and Atherosclerosis Research Group, Clinical Research Institute of Montreal, Montreal, Quebec, Canada (J.F., S.L.-C., J.D.).

Correspondence to Dr S. Lussier-Cacan, Hyperlipidemia and Atherosclerosis Research Group, Clinical Research Institute of Montreal, 110 Pine Ave W, Montreal, Quebec, Canada H2W 1R7.


*    Abstract
up arrowTop
 *Abstract
down arrowIntroduction
 down arrowMethods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Background Familial hypercholesterolemia (FH), an autosomal codominant disease, is characterized by high levels of LDL cholesterol and a high incidence of coronary artery disease (CAD). To date, genetic heterogeneity has hindered the proper assessment of the relation between risk factors and CAD in FH patients.

Methods and Results We studied the association between CAD and common risk factors in a sample of 263 French Canadian FH patients (147 women, 116 men) carrying the same >10-kb deletion of the LDL receptor gene. Thirty-five women and 54 men had CAD. The mean age of onset of CAD was 45.6±12.7 years in women and 38.8±9.4 years in men. Multiple logistic regression analyses were performed to test the association between CAD and age, tendon xanthomas, cigarette smoking, hypertension, diabetes mellitus, apolipoprotein E polymorphism, total plasma cholesterol, triglycerides, VLDL cholesterol, LDL cholesterol, HDL cholesterol, and lipoprotein(a) [Lp(a)]. In FH women, significant multivariate predictors were age (odds ratio, 1.10 for 1 year; P<.0001), VLDL cholesterol (odds ratio, 3.85 for 1 natural log unit; P<.002), and LDL cholesterol (odds ratio, 1.42 for 1 mmol/L; P<.02). In FH men, age (odds ratio, 1.08 for 1 year; P<.0001) and HDL cholesterol (odds ratio, 0.14 for 1 mmol/L; P=.05) were significant predictors of disease. Lp(a) was not a significant predictor in univariate or multivariate analyses.

Conclusions This study suggests that increased risk of CAD in FH is not solely due to elevated LDL cholesterol levels and demonstrates a sex-specific lipoprotein influence on CAD in a large sample of FH patients carrying the same LDL receptor gene defect.


Key Words: hypercholesterolemia • coronary disease • risk factors


*    Introduction
up arrowTop
 up arrowAbstract
 *Introduction
down arrowMethods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Coronary artery disease (CAD) is the leading cause of death both in women and men in industrialized countries. The identification of subjects at risk of developing CAD is an important public health issue. Epidemiological and clinical studies have demonstrated that elevated LDL cholesterol levels are associated with an increased risk of CAD,1 whereas HDL cholesterol levels are inversely related to the risk of CAD.1 2 Furthermore, treatments that significantly lower LDL cholesterol (LDL-C), with and without significant increases in HDL cholesterol (HDL-C), have reduced the rate of fatal and nonfatal cardiac events3 4 5 and, in selected patients, have diminished coronary artery narrowing.6 Whether elevated plasma triglyceride (TG) levels act as an independent risk factor for CAD is controversial,2 7 8 9 although several studies have suggested that TG levels are an important risk factor for CAD in women.10 11 Similarly, the relation between lipoprotein(a) [Lp(a)] and CAD still requires clarification.12 13 In cross-sectional studies, elevated LDL-C levels, low HDL-C levels, hypertriglyceridemia, and Lp(a) excess have been associated with premature CAD.10 14

Familial hypercholesterolemia (FH) is characterized by markedly elevated LDL-C levels and premature CAD. It is an autosomal codominant disease defined at the molecular level by one of a number of mutations in the LDL receptor gene.15 16 Despite the hereditary nature of the disease, FH shows great variability in phenotypic expression.17 Such interindividual phenotypic variation in heterozygous FH patients could be explained by the variability of the underlying mutation.18 19 20 Other genetic influences, such as apolipoprotein (apo) E polymorphism, also appear to play an important role.21 22 The expression of this disease may be affected by age,23 sex,24 25 other risk factors such as smoking and hypertension,24 or associated lipid abnormalities such as low HDL-C levels,24 25 26 27 28 high TG levels,24 27 29 30 high Lp(a) levels,28 29 30 or presence of type III dyslipoproteinemia.31 FH is one of the more common inherited metabolic diseases, with a prevalence of 1 in 500 heterozygotes in most populations.15 However, in French Canadians,32 33 Finns,18 19 and Afrikaners in South Africa,20 frequencies of FH are much higher because of a founder effect.34 Indeed, one of the founder mutations, a >10-kb deletion of the 5' end of the LDL receptor gene including the promoter and exon 1, has been observed in 60% of French Canadian FH patients.35

In previous studies, genetic heterogeneity has hindered the proper assessment of the relation between risk factors and CAD in FH patients. The present study was undertaken to examine the association between various risk factors and CAD in a sample of FH patients, all carriers of the >10-kb deletion of the LDL receptor gene, and to assess whether factors other than increased LDL-C levels could explain the variability in phenotypic expression in FH. In addition, because we have previously reported that even in such a homogeneous group of FH patients, considerable sex differences can be observed in the means, variances, and correlations of lipid levels36 as well as in the influence of concomitants such as age, height, and weight on lipid variables,37 we have performed the analyses separately by sex.


*    Methods
up arrowTop
 up arrowAbstract
 up arrowIntroduction
 *Methods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Subjects
FH subjects were selected from 383 untreated patients who had been referred to the Lipid Clinic of the Clinical Research Institute of Montreal and who were heterozygous for the >10-kb deletion of the LDL receptor gene as determined by Southern blot analysis.35 38 Two hundred sixty-three FH adult patients (age >18 years) from 167 families for whom complete clinical and biological data were available were included in the study. All of these FH (10-kb FH) patients (147 women, 116 men) had elevated LDL-C levels (LDL-C >4.2 mmol/L) and either tendon xanthomas or a history of tendon xanthomas in a first-degree relative.16

Determination of CAD
Patients were classified according to the presence (n=89) or absence (n=174) of symptomatic CAD. Medical records were obtained for all CAD cases. CAD was considered to be present if patients had a documented history of myocardial infarction, an abnormal coronary angiogram (stenosis >70% in a major vessel), percutaneous transluminal coronary angioplasty, or coronary artery bypass grafting (n=83) or if patients had a history of angina together with either a positive exercise test or an abnormal stress thallium-201 scan (n=6). None of the patients had suffered a major CAD event within the preceding 6 months. For each patient, the age of onset of CAD was defined as the age of the first CAD symptoms ascertained by a standard questionnaire administered by a physician of our Lipid Clinic.

Clinical Risk Factors
Body mass index (BMI) was calculated as weight divided by height squared (kg/m2). Cigarette smoking was assessed by self-report, and subjects were classified as current smokers, former smokers, or never-smokers. Blood pressure was measured on subjects in the supine position after a 5-minute rest. Subjects were classified as hypertensive if they were being treated with drugs for previously diagnosed hypertension, if systolic blood pressure was >=160 mm Hg, or if diastolic blood pressure was >=95 mm Hg. A patient was classified as having diabetes if she or he was receiving drug treatment for diabetes or if the fasting plasma glucose concentration was >=7.8 mmol/L.

Biological Risk Factors and Laboratory Methods
After a 12-hour overnight fast, blood samples were obtained in tubes containing 1.5 mg/mL Na2 EDTA (lipids, lipoproteins) or no anticoagulant (glucose) and were centrifuged within 2 hours. Plasma lipoproteins were separated under standard conditions by a combination of ultracentrifugation at d=1.006 g/mL to isolate VLDL and heparin-manganese precipitation of apo B–containing lipoproteins in the d=1.006 g/mL infranatant to determine LDL-C and HDL-C concentrations according to the Lipid Research Clinics Protocol.39 Plasma and lipoprotein cholesterol and TG were measured enzymatically using an automated analyzer (Roche Cobas Mira S; F. Hoffmann-La Roche and Co, Ltd; Diagnostica). Apo E phenotypes were determined after isoelectric focusing of VLDL apoproteins.40 Lp(a) was measured in plasma using a commercially available ELISA (Macra, Terumo Medical Corp). Fasting plasma glucose was determined by the glucose oxidase method (Boehringer Mannheim).

Statistical Analysis
Epidemiological studies have shown that the frequency distributions of plasma lipids differ according to sex. Specifically, in the 10-kb FH population, striking differences in means, variances, and correlations of clinical and lipid parameters between women and men have been reported.36 37 Analyses were therefore performed separately for women and men. Evidence for statistically significant quantitative trait differences between patients with and without CAD was evaluated by use of the Student's t test with Satterthwaite's correction to take into account heteroscedasticity of variances whenever necessary. Because the distributions of Lp(a), TG, and VLDL cholesterol (VLDL-C) values were highly skewed, a natural logarithmic transformation was performed. The Pearson's {chi}2 test was used to assess differences in the distributions of categorical traits. All tests were two-sided, and the significance level was set at .05. Because of the multicollinearity among the parameters studied, these univariate analyses must be examined with caution.

The relations between demographic, clinical, and biological parameters and the presence or absence of CAD were examined by multiple logistic regression.41 Likelihood ratio statistics were used to compare models with different combinations of predictors. Both forward stepwise and backward stepwise trait selection procedures were used to identify a parsimonious set of predictors with an inclusion significance level of .15 and an exclusion significance level of .20. Forward stepwise trait selection was also carried out to identify pairwise interactions. The predictors in the most complete logistic regression model, identified by the stepwise procedure, were then evaluated by the likelihood ratio test statistic with a significance level of .05. Finally, an analysis of model fit was undertaken. First, the goodness of fit of the final models was evaluated with the {chi}2HL statistic of Hosmer and Lemeshow.41 Second, diagnostic statistics (leverages, studentized deleted residuals, Cook's distances) were obtained to identify observations that may have unduly influenced model fit. Given the number of CAD events in the sample, our study had a power of 0.80, in each sex, to detect an odds ratio of 1.8 for an FH patient with a risk factor of 1 SD above the mean, when controlling for all other variables using a test with a significance level of .05.42


*    Results
up arrowTop
 up arrowAbstract
 up arrowIntroduction
 up arrowMethods
*Results
down arrowDiscussion
down arrowReferences
 
Clinical Data
Clinical findings are listed in Tables 1Down and 2Down for 10-kb FH women and men, respectively. At the time of the study, the mean age of patients with CAD [CAD(+)] was significantly higher (P<.0001) than the mean age of patients without CAD [CAD(-)] for each sex. The mean age of onset of CAD was 45.6±12.7 years in women and 38.8±9.4 years in men. Symptomatic CAD occurred 7 years later in women than in men (P<.01). In each sex, anthropometric data (height, weight, and body mass index) did not differ between CAD(+) and CAD(-) groups. The prevalence of tendon xanthomas was significantly higher in CAD(+) than in CAD(-) for women only. There was no difference in the frequencies of the common risk factors for the CAD(+) and CAD(-) groups except for a significantly higher frequency of hypertension in women with than in women without CAD.


View this table:
[in this window]
[in a new window]
  		Table 1. Clinical and Biological Features of 147 Familial Hypercholesterolemia Women With the LDL Receptor Gene >10-kb Deletion


View this table:
[in this window]
[in a new window]
  		Table 2. Clinical and Biological Features of 116 Familial Hypercholesterolemia Men With the LDL Receptor Gene >10-kb Deletion

Lipid and Lipoprotein Levels
The mean concentrations of plasma lipids and lipoproteins in the CAD(+) and CAD(-) FH groups are summarized in Tables 1Up and 2Up for women and men, respectively. In women, CAD(+) patients had significantly higher plasma levels of total cholesterol, VLDL-C and LDL-C, and TG than did CAD(-) patients. In contrast, the only significant difference between CAD(+) and CAD(-) men was the level of HDL-C, which was lower in men with than in men without CAD. There was no difference in Lp(a) levels between CAD(+) and CAD(-) patients of either sex.

Apo E Polymorphism and CAD
The apo E phenotype distribution did not differ between 10-kb FH CAD(+) and CAD(-) groups for either sex. In particular, there was no increased frequency of the E4/3 and E4/4 phenotypes in CAD(+) groups (not shown).

Multivariate Analysis
Sex-specific multiple logistic regression analyses are presented in Table 3Down. In 10-kb FH women, selection procedures identified age, VLDL-C, and LDL-C as predictors of the probability of having CAD. The odds of having CAD increased with increasing age, VLDL-C, and LDL-C. In 10-kb FH men, multiple logistic regression analysis demonstrated that age and HDL-C were associated with CAD. The odds of having CAD increased with increasing age and with decreasing HDL-C. No pairwise interactions attained the significance level of .05. Nonsignificant values of the {chi}2HL statistics suggested that the models presented in Table 3Down fit the observed outcomes well ({chi}2HL=5.1, df=8, and {chi}2HL=14.4, df=8 for women and men, respectively). Diagnostic statistics revealed no outlier or influential observations. Because of the family relationships within the study sample (and therefore a possible statistical dependence) and because of the known effects of ß-blocker therapy on lipid levels, we repeated our analysis on the reduced sample of 167 unrelated 10-kb FH probands as well as on the entire sample after excluding patients with ß-blocker medication. Similar results were obtained in both analyses (data not shown).


View this table:
[in this window]
[in a new window]
  		Table 3. Parameters Associated With Coronary Artery Disease in Familial Hypercholesterolemia Patients With the >10-kb Deletion of the LDL Receptor Gene by Multiple Logistic Regression Analysis


*    Discussion
up arrowTop
 up arrowAbstract
 up arrowIntroduction
 up arrowMethods
up arrowResults
*Discussion
down arrowReferences
 
The early development of CAD in FH is largely attributed to elevated LDL-C levels.15 16 However, it is likely that other lipid and nonlipid factors also influence CAD risk in these patients. The availability of a large sample of FH individuals with an identical LDL receptor gene deletion of >10 kb has enabled us to study the potential causes of variability in CAD expression in 10-kb FH. In the absence of the etiologic heterogeneity found in other clinically defined FH samples, our data suggest a sex-specific lipoprotein effect on CAD in FH patients, such that different lipoproteins influenced CAD risk differently in each sex.

In the general population, CAD rates are higher in elderly compared with younger individuals.1 In agreement with previous studies, we found that age is also associated with CAD in 10-kb FH. Mabuchi et al23 reported that the onset and progression of CAD in FH, estimated by angiography, were correlated with age. In multiple regression analyses, Wiklund et al29 and Tatò et al25 found that age significantly predicted CAD in FH. Our study also revealed that the mean age of onset of coronary symptoms was 45.6 years in women and 38.8 years in men. Thus, CAD apparently occurs earlier in >10-kb FH patients than in other FH groups.30 43 The 7-year delay in 10-kb FH women, relative to men, is also lower than the 10-year delay generally found in different FH populations.24 26 28 These observations suggest that the >10-kb deletion of the LDL receptor gene, which results in a null allele, is associated with more precocious and severe forms of CAD in heterozygous FH patients (this study) as well as in homozygous FH patients17 than in other FH samples.

In 10-kb FH men, both age and HDL-C appeared to be independent predictors for CAD. Many epidemiological studies in high-risk populations have shown that low HDL-C level is a significant risk factor.2 In the Lipid Research Clinics Follow-up Study, HDL-C levels were strongly inversely associated with mortality from CAD at higher LDL-C levels (LDL-C >160 mg/dL), although not at lower LDL-C levels, in both women and men.9 Low HDL-C levels in FH subjects have been associated with CAD in several studies.24 25 26 27 28 This relation was found in both sexes,27 only in women,26 or only in men24 in univariate analyses. After adjustment for age and sex, HDL2-C levels were lower in FH patients with CAD in the study of Mbewu et al.28 In a recent study in 91 FH patients, age, sex, and HDL-C levels were the only variables reaching statistical significance in multiple logistic regression.25 These results suggest that, even in the presence of very high LDL-C levels, as seen in FH, reverse cholesterol transport assumes the same importance as in nonselected populations.1 2

In contrast with men, the best predictors of CAD in women in the present study were age, VLDL-C levels, and LDL-C levels. In 30 CAD patients who were matched for age and sex with 30 FH patients who had not developed CAD, LDL-C was found to be higher in those with CAD.28 The role of LDL-C levels as a risk factor for CAD in FH women was difficult to establish in previous studies because of the heterogeneity of the samples studied. In a clinically defined sample, mutations of the LDL receptor gene underlying FH may be numerous in the absence of a genetic founder effect.34 In French Canadians, total plasma cholesterol and LDL-C levels were found to be higher in FH homozygotes with the >10-kb deletion than in those with the exon 3 mutation of the LDL receptor gene and to result in earlier manifestations of CAD.17 Our results show that, among women with the same >10-kb LDL receptor gene deletion, the severity of the LDL-C excess has an impact on CAD risk in heterozygous 10-kb FH. The greater variability in LDL-C levels found in 10-kb FH women than in men may partly explain the sex-specific effect of LDL-C on CAD expression.

A striking finding of our study was the strong association of VLDL-C levels with CAD in 10-kb FH women. When we tested a complete model that included age, LDL-C, and the ratio of VLDL-C to plasma TG, or an estimate of ß-VLDL31 in the >10-kb FH women, the predictive power of this model for CAD was similar to that of the best model we found for women including age, LDL-C, and VLDL-C (data not shown). The role of TG-rich lipoproteins in the development of CAD in FH has been suggested by previous studies. In the work of Hirobe et al,27 mean TG levels were significantly higher in patients with CAD than in patients without CAD, but only in women. In a recent study, higher plasma TG concentration was the only significant difference between FH female patients with and without CAD.24 In Quebec, the prevalence of myocardial infarction was found to be three times greater in type IIb (TG >200 mg/dL) than in type IIa familial hypercholesterolemia patients.44 In a recent study by Wiklund et al,29 the group of FH patients with CAD had higher levels of TG by univariate analysis, but this difference disappeared in multivariate analysis. In the work of Seed et al,30 multiple discriminant analysis retained TG levels as an independent risk factor for CAD in FH. Two recent studies have indicated that there is an excess risk of CAD in the presence of TG >2.3 mmol/L when the ratio of LDL-C to HDL-C exceeds 5.7 8

It is likely that fasting TG as measured in the above studies may inadequately reflect the chronic effects of TG-rich lipoproteins. Postprandial lipoproteins such as chylomicron remnants, intermediate-density lipoprotein, VLDL, or particles of different size and composition may be more closely related to CAD.2 Catabolism of the TG-rich lipoproteins produces remnant particles that appear to be atherogenic,45 46 47 48 whereas newly secreted VLDL and chylomicrons that are rich in TG and low in cholesterol esters are less atherogenic. The distribution of apo CIII between VLDL and HDL, a crude index of TG metabolic capacity, emerged as the most powerful predictor of CAD angiographic progression in drug-treated patients.49 Comparison of FH and non-FH subjects showed a markedly higher ratio of VLDL-C to plasma TG and a fivefold increase in mean estimated ß-VLDL among FH subjects.31 In a kinetic study of different VLDL subfractions in homozygous FH patients, James et al50 found fourfold increases in intermediate-density lipoprotein and less marked increases in small VLDL, while concentrations of larger VLDL were unaltered compared with those of control subjects. Furthermore, the smaller VLDL in FH homozygotes were enriched with cholesterol and depleted in TG.50 These smaller cholesterol ester–enriched VLDL share with LDL the ability to deliver cholesterol to the arterial intima in humans.51 FH is primarily characterized by overproduction and slow catabolism of LDL.52 However, impaired catabolism of VLDL and its remnants is also a recognized feature of FH.52

Whether Lp(a) is a risk factor for CAD in FH is unclear. Lp(a) was found to be a powerful predictor of CAD in FH in two studies,29 30 whereas no such relation was found in three other studies.25 28 53 In the last study53 conducted in FH patients with a heterogeneous genetic background, plasma Lp(a) levels that were found to be higher than in a control population were not associated with a higher risk for developing CAD. In the present study, we did not find any significant association of Lp(a) with CAD in women or in men. All the patients of our sample share the same mutation of the LDL receptor gene, whereas in previous studies,28 29 30 53 the diagnosis of FH was established on clinical findings. In a recent study of 91 FH patients who were only partly genetically defined (36 of 91), Lp(a) was not associated with CAD in multiple logistic regression.25 These results suggest that Lp(a) levels alone are not a strong risk factor for CAD in FH. However, in some groups of young patients14 or in FH patients with particular apo(a) phenotypes,30 53 the risk of CAD may be increased.

In our study, the distribution of apo E phenotypes was similar in patients with and without CAD in both sexes. This result contrasts with reports in the general population showing an increased prevalence of the {varepsilon}4 allele in patients with symptomatic CAD.54 Only one previous study has shown an effect of apo E phenotypes on CAD in FH, in which a significantly higher prevalence of CAD was observed among apo E4 carriers.21 Our work adds to previous negative findings of the influence of apo E polymorphism on CAD in FH18 24 and suggests that a major gene effect, the >10-kb deletion of the LDL receptor gene, may mask the discrete impact of apo E on CAD.54

The present study contains limitations inherent to the study design. This investigation was cross-sectional and was based on the evaluation of the presence of symptomatic CAD. Coronary arteriography was not performed routinely on asymptomatic FH patients. Since severe coronary lesions may exist without symptoms, symptomatic CAD is therefore an inaccurate measure for the presence and the extent of CAD and may result in occasional misclassifications. The relations between CAD and the predictors that we found in the 10-kb FH patients should be confirmed by other studies designed specifically to evaluate the incidence of CAD in relation to selected risk factors. Prospective studies are thus required to establish the effects of lipoproteins on CAD risk in FH.

Conclusions
Our study shows a sex-specific lipoprotein influence on CAD in a large sample of FH patients carrying a particular LDL receptor gene deletion. Age is a powerful risk factor for CAD in 10-kb FH in both sexes, in addition to lower HDL-C levels in 10-kb FH men and higher VLDL-C and LDL-C levels in 10-kb FH women. CAD risk in 10-kb FH is therefore not solely attributable to high LDL concentrations. Even in the presence of overt hypercholesterolemia, the pathological expression of 10-kb FH is markedly affected by other lipoproteins in a sex-specific manner, supporting the view that CAD in FH can be influenced both by genetic and environmental factors.


*    Acknowledgments
 
This work was supported by grants from the Medical Research Council of Canada/CIBA-GEIGY Canada Ltd (UI-11407), by the Heart and Stroke Foundation of Quebec, and by La Succession J.A. DeSève. J.F. is the recipient of a scholarship from le Comité français de coordination des recherches sur l'athérosclérose et le cholestérol (ARCOL). We would like to thank Daniel Bouthillier, Denise Dubreuil, Madeleine Roy, and Lisa Tassoni for helpful discussion, and we thank Dorota Taraszkiewicz for preparing the manuscript. We are grateful to Jeffrey Cohn, Jacques Genest, Jr, and Anne Minnich for critical reading of the manuscript.

Received December 5, 1994; accepted January 28, 1995.


*    References
up arrowTop
 up arrowAbstract
 up arrowIntroduction
 up arrowMethods
up arrowResults
up arrowDiscussion
*References
 

  1. National Cholesterol Education Program Expert Panel. Second report of the Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults. Circulation. 1994;89:1329-1445.
  2. NIH Consensus Development Panel on Triglyceride, High-Density Lipoprotein, and Coronary Heart Disease. Triglyceride, high-density lipoprotein, and coronary heart disease. JAMA. 1993;269:505-510. [Medline] [Order article via Infotrieve]
  3. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results, I: reduction in incidence of coronary heart disease. JAMA. 1984;251:351-364. [Abstract]
  4. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results, II: the relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA. 1984;251:365-374. [Abstract]
  5. Frick MH, Elo MO, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitanieni P, Koskinen P, Manninen V, Mäenpää H, Mälkönen M, Mänttäri M, Norola S, Paternack A, Pikkarainen J, Romo M, Sjöblom T, Nikkilä EA. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987;317:1237-1245. [Abstract]
  6. Blankenhorn DH, Hodis HN. Arterial imaging and atherosclerosis reversal. Arterioscler Thromb. 1994;14:177-192. [Abstract/Free Full Text]
  7. Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Am J Cardiol. 1992;70:733-737. [Medline] [Order article via Infotrieve]
  8. Manninen V, Tenkanen L, Koskinen P, Huttunen JK, Mänttäri M, Heinonen OP, Frick MH. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Circulation. 1992;85:37-45. [Abstract/Free Full Text]
  9. Criqui MH, Heiss G, Cohn R, Cowan LD, Suchindran CM, Bangdiwala S, Kritchevsky S, Jacobs DR Jr, O'Grady HK, Davis CE. Plasma triglyceride level and mortality from coronary heart disease. N Engl J Med. 1993;328:1220-1225. [Abstract/Free Full Text]
  10. Nieminen MS, Matila KJ, Aalto-Setälä K, Kuusi T, Kontula K, Kauppinen-Mäkelin R, Ehnholm C, Jauhiainen M, Valle M, Taskinen MR. Lipoproteins and their genetic variation in subjects with and without angiographically verified coronary artery disease. Arterioscler Thromb. 1992;12:58-69. [Abstract/Free Full Text]
  11. Bass KM, Newschaffer CJ, Klag MJ, Bush TL. Plasma lipoprotein levels as predictors of cardiovascular death in women. Arch Intern Med. 1993;153:2209-2216. [Abstract]
  12. Ridker PM, Hennekens CH, Stampfer MJ. A prospective study of lipoprotein(a) and the risk of myocardial infarction. JAMA. 1993;270:2195-2199. [Abstract]
  13. Schaefer EJ, Lamon-Fava S, Jenner JL, McNamara JR, Ordovas JM, Davis CE, Abolafia JM, Lippel K, Levy RI. Lipoprotein(a) levels and risk of coronary heart disease in men: the Lipid Research Clinics Coronary Primary Prevention Trial. JAMA. 1994;271:999-1003. [Abstract]
  14. Genest J Jr, McNamara PM, Ordovas JM, Jenner JL, Silberman SR, Anderson KM, Wilson PWF, Salem DN, Schaefer EJ. Lipoprotein cholesterol, apolipoprotein A-I and B and lipoprotein(a) abnormalities in men with premature coronary artery disease. J Am Coll Cardiol. 1992;19:792-802. [Abstract]
  15. Goldstein JL, Brown MS. Familial hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic Basis of Inherited Disease. New York, NY: McGraw-Hill; 1989:1195-1250.
  16. Davignon J, Roy M, Dufour R, Roederer G. Familial hypercholesterolemia. In: Steiner G, Shafrir E, eds. The Hyperlipidemias, vol 1: Primary Hyperlipidemias. New York, NY: McGraw-Hill; 1991:201-234.
  17. Moorjani S, Roy M, Torres A, Bétard C, Gagné C, Lambert M, Brun D, Davignon J, Lupien P. Mutations of low-density lipoprotein receptor gene, variation in plasma cholesterol, and expression of coronary heart disease in homozygous familial hypercholesterolaemia. Lancet. 1993;341:1303-1306. [Medline] [Order article via Infotrieve]
  18. Gylling H, Aalto-Setälä K, Kontula K, Miettinen TA. Serum low-density lipoprotein cholesterol level and cholesterol absorption efficiency are influenced by apolipoprotein B and E polymorphism and by the FH-Helsinki mutation of the low-density lipoprotein receptor gene in familial hypercholesterolemia. Arterioscler Thromb. 1991;11:1368-1375. [Abstract/Free Full Text]
  19. Koivisto PVI, Koivisto UM, Kovanen PT, Gylling H, Miettinen TA, Kontula K. Deletion of exon 15 of the LDL receptor gene is associated with a mild form of familial hypercholesterolemia: FH-Espoo. Arterioscler Thromb. 1993;13:1680-1688. [Abstract/Free Full Text]
  20. Kotze MJ, De Villiers WJS, Steyn K, Kriek JA, Marais AD, Langenhoven E, Herbert JS, Graadt Van Roggen JF, Van der Westhuyzen DR, Coetzee GA. Phenotypic variation among familial hypercholesterolemics heterozygous for either one of two Afrikaner founder LDL receptor mutations. Arterioscler Thromb. 1993;13:1460-1468. [Abstract/Free Full Text]
  21. Eto M, Watanabe K, Chonan N, Ishii K. Familial hypercholesterolemia and apolipoprotein E4. Atherosclerosis. 1988;72:123-128. [Medline] [Order article via Infotrieve]
  22. Dallongeville J, Roy M, Leboeuf N, Xhignesse M, Davignon J, Lussier-Cacan S. Apolipoprotein E polymorphism association with lipoprotein profile in endogenous hypertriglyceridemia and familial hypercholesterolemia. Arterioscler Thromb. 1991;11:272-278. [Abstract/Free Full Text]
  23. Mabuchi H, Koizumi J, Shimuzu M, Takeda R, Hokuriku FH, CHD Study Group. Development of coronary disease in familial hypercholesterolemia. Circulation. 1989;79:225-232. [Abstract/Free Full Text]
  24. Hill JS, Hayden MR, Frohlich J, Pritchard PH. Genetic and environmental factors affecting the incidence of coronary artery disease in heterozygous familial hypercholesterolemia. Arterioscler Thromb. 1991;11:290-297. [Abstract/Free Full Text]
  25. Tatò F, Keller C, Schuster H, Spengel F, Wolfram G, Zöllner N. Relation of lipoprotein(a) to coronary heart disease and duplexsonographic findings of the carotid arteries in heterozygous familial hypercholesterolemia. Atherosclerosis. 1993;101:69-77.[Medline] [Order article via Infotrieve]
  26. Gagné C, Moorjani S, Brun D, Toussaint M, Lupien PJ. Heterozygous familial hypercholesterolemia. Atherosclerosis. 1979;34:13-24. [Medline] [Order article via Infotrieve]
  27. Hirobe K, Matsuzawa Y, Ishikawa S, Yamamoto A, Nambu S, Fujimoto K. Coronary artery disease in heterozygous familial hypercholesterolemia. Atherosclerosis. 1982;44:201-210. [Medline] [Order article via Infotrieve]
  28. Mbewu AD, Bhatnagar D, Durrington PN, Hunt L, Ishola M, Arrol S, Mackness M, Lockley P, Miller JP. Plasma lipoprotein(a) in patients heterozygous for familial hypercholesterolemia, their relatives, and unrelated control populations. Arterioscler Thromb. 1991;11:940-946. [Abstract/Free Full Text]
  29. Wiklund O, Angelin B, Olofsson SO, Eriksson M, Fager G, Berglund L, Bondjers G. Apolipoprotein(a) and ischaemic heart disease in familial hypercholesterolaemia. Lancet. 1990;335:1360-1363. [Medline] [Order article via Infotrieve]
  30. Seed M, Hoppichler F, Reaveley D, McCarthy SN, Thompson GR, Boerwinkle E, Utermann G. Relation of plasma lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia. N Engl J Med. 1990;322:1494-1499. [Abstract]
  31. Hopkins PN, Wu LL, Schumacher MC, Emi M, Hegele RM, Hunt SC, Lalouel JM, Williams RR. Type III dyslipoproteinemia in patients heterozygous for familial hypercholesterolemia and apolipoprotein E2. Arterioscler Thromb. 1991;11:1137-1146. [Abstract/Free Full Text]
  32. Moorjani S, Roy M, Gagné C, Davignon J, Brun D, Toussaint M, Lambert M, Campeau L, Blaichman S, Lupien P. Homozygous familial hypercholesterolemia among French Canadians in Québec Province. Arteriosclerosis. 1989;9:211-216. [Abstract/Free Full Text]
  33. Bétard C, Kessling AM, Roy M, Chamberland A, Lussier-Cacan S, Davignon J. Molecular genetic evidence for a founder effect in familial hypercholesterolemia among French Canadians. Hum Genet. 1992;88:529-536. [Medline] [Order article via Infotrieve]
  34. Davignon J, Roy M. Familial hypercholesterolemia in French-Canadians: taking advantage of the presence of a `founder effect.' Am J Cardiol. 1993;72:6D-10D. [Medline] [Order article via Infotrieve]
  35. Hobbs HH, Brown MS, Russell DW, Davignon J, Goldstein JL. Deletion in the gene for the low-density-lipoprotein receptor in a majority of French Canadians with familial hypercholesterolemia. N Engl J Med. 1987;317:734-737. [Abstract]
  36. Roy M, Sing CF, Bétard C, Davignon J. Impact of a common mutation of the LDL receptor gene in French Canadian patients with familial hypercholesterolemia, on means, variances and covariances among traits of lipid metabolism. Clin Genet. 1995;47:59-67. [Medline] [Order article via Infotrieve]
  37. Ferrières J, Sing CF, Roy M, Davignon J, Lussier-Cacan S. Apolipoprotein E polymorphism and heterozygous familial hypercholesterolemia: gender-specific effects. Arterioscler Thromb. 1994;14:1553-1560. [Abstract/Free Full Text]
  38. Ma Y, Bétard C, Roy M, Davignon J, Kessling AM. Identification of a second `French Canadian' LDL receptor gene deletion and development of a rapid method to detect both deletions. Clin Genet. 1989;36:219-228. [Medline] [Order article via Infotrieve]
  39. Lipid Research Clinics Program Epidemiology Committee. Plasma lipid distribution in selected North American populations: the Lipid Research Clinics Program prevalence study. Circulation. 1979;60:427-439. [Abstract/Free Full Text]
  40. Bouthillier D, Sing CF, Davignon J. Apolipoprotein E phenotyping with a single gel method: application to the study of informative matings. J Lipid Res. 1983;24:1060-1069. [Abstract]
  41. Hosmer DW, Lemeshow S. Applied Logistic Regression. New York, NY: John Wiley & Sons; 1989:307.
  42. Hsieh FY. Sample size tables for logistic regression. Stat Med. 1989;8:795-802. [Medline] [Order article via Infotrieve]
  43. Stone NJ, Levy RI, Fredrickson DS, Verter J. Coronary artery disease in 116 kindred with familial type II hyperlipoproteinemia. Circulation. 1974;49:476-488. [Abstract/Free Full Text]
  44. Moorjani S, Gagné C, Lupien PJ, Brun D. Plasma triglycerides related decrease in high-density lipoprotein cholesterol and its association with myocardial infarction in heterozygous familial hypercholesterolemia. Metabolism. 1986;35:311-316. [Medline] [Order article via Infotrieve]
  45. Tatami R, Mabuchi H, Ueda K, Ueda R, Haba T, Kametani T, Ito S, Koizumi J, Ohta M, Miyamoto S, Nakayama A, Kanaya H, Oiwake H, Genda A, Takeda R. Intermediate-density lipoprotein and cholesterol-rich very low-density lipoprotein in angiographically determined coronary artery disease. Circulation. 1981;64:1174-1184. [Abstract/Free Full Text]
  46. Reardon MF, Nestel PJ, Craig IH, Harper RW. Lipoprotein predictors of the severity of coronary disease in men and women. Circulation. 1985;71:881-888. [Abstract/Free Full Text]
  47. Steiner G, Schwartz L, Shumak S, Poapst M. The association of increased levels of intermediate-density lipoproteins with smoking and with coronary artery disease. Circulation. 1987;75:124-130. [Abstract/Free Full Text]
  48. Phillips NR, Waters D, Havel RJ. Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events. Circulation. 1993;88:2762-2770. [Abstract/Free Full Text]
  49. Blankenhorn DH, Alaupovic P, Wickham E, Chin HP, Azen SP. Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts: lipid and nonlipid factors. Circulation. 1990;81:470-476. [Abstract/Free Full Text]
  50. James RW, Martin B, Pometta D, Fruchart JC, Duriez P, Puchois P, Farriaux JP, Tacquet A, Demant T, Clegg RJ, Munro A, Oliver MF, Packard CJ, Shepherd J. Apolipoprotein B metabolism in homozygous familial hypercholesterolemia. J Lipid Res. 1989;30:159-169. [Abstract]
  51. Shaikh M, Wootton R, Nordestgaard B, Baskerville P, Lumley JL, La Ville A, Quiney J, Lewis B. Quantitative studies of transfer in vivo of low-density, Sf 12-60, and Sf 60-400 lipoproteins between plasma and arterial intima in humans. Arterioscler Thromb. 1991;11:569-577. [Abstract/Free Full Text]
  52. Fisher WR, Zech LA, Stacpoole PW. ApoB metabolism in familial hypercholesterolemia: inconsistencies with the LDL receptor paradigm. Arterioscler Thromb. 1994;14:501-510. [Abstract/Free Full Text]
  53. Bowden J-F, Pritchard PH, Hill JS, Frolich JJ. Lp(a) concentration and apo(a) isoform size: relation to the presence of coronary artery disease in familial hypercholesterolemia. Arterioscler Thromb. 1994;14:1561-1568. [Abstract/Free Full Text]
  54. Davignon J. Apolipoprotein E polymorphism and atherosclerosis. In: Born GVR, Schwartz CJ, eds. New Horizons in Coronary Heart Disease. London: Current Science; 1993:5.1-5.21.



This article has been cited by other articles:


Home page
 Eur Heart JHome page
J. B. van der Net, D. M. Oosterveer, J. Versmissen, J. C. Defesche, M. Yazdanpanah, B. E. Aouizerat, E. W. Steyerberg, M. J. Malloy, C. R. Pullinger, J. J.P. Kastelein, et al.
Replication study of 10 genetic polymorphisms associated with coronary heart disease in a specific high-risk population with familial hypercholesterolemia
Eur. Heart J., July 3, 2008; (2008) ehn303v1.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
J. B. van der Net, J. van Etten, M. Yazdanpanah, G. M. Dallinga-Thie, J. J.P. Kastelein, J. C. Defesche, R. P. Koopmans, E. W. Steyerberg, and E. J.G. Sijbrands
Gene-load score of the renin-angiotensin-aldosterone system is associated with coronary heart disease in familial hypercholesterolaemia
Eur. Heart J., June 1, 2008; 29(11): 1370 - 1376.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
M. L. E. MacDonald, R. R. Singaraja, N. Bissada, P. Ruddle, R. Watts, J. M. Karasinska, W. T. Gibson, C. Fievet, J. E. Vance, B. Staels, et al.
Absence of stearoyl-CoA desaturase-1 ameliorates features of the metabolic syndrome in LDLR-deficient mice
J. Lipid Res., January 1, 2008; 49(1): 217 - 229.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
M. Junyent, M. Cofan, I. Nunez, R. Gilabert, D. Zambon, and E. Ros
Influence of HDL Cholesterol on Preclinical Carotid Atherosclerosis in Familial Hypercholesterolemia
Arterioscler. Thromb. Vasc. Biol., May 1, 2006; 26(5): 1107 - 1113.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
D. T. Holmes, B. A. Schick, K. H. Humphries, and J. Frohlich
Lipoprotein(a) Is an Independent Risk Factor for Cardiovascular Disease in Heterozygous Familial Hypercholesterolemia
Clin. Chem., November 1, 2005; 51(11): 2067 - 2073.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
M. Junyent, R. Gilabert, D. Zambon, I. Nunez, M. Vela, F. Civeira, M. Pocovi, and E. Ros
The Use of Achilles Tendon Sonography to Distinguish Familial Hypercholesterolemia from Other Genetic Dyslipidemias
Arterioscler. Thromb. Vasc. Biol., October 1, 2005; 25(10): 2203 - 2208.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
F. Civeira, S. Castillo, R. Alonso, E. Merino-Ibarra, A. Cenarro, M. Artied, P. Martin-Fuentes, E. Ros, M. Pocovi, P. Mata, et al.
Tendon Xanthomas in Familial Hypercholesterolemia Are Associated With Cardiovascular Risk Independently of the Low-Density Lipoprotein Receptor Gene Mutation
Arterioscler. Thromb. Vasc. Biol., September 1, 2005; 25(9): 1960 - 1965.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
A. C.M. Jansen, E. S. van Aalst-Cohen, M. W.T. Tanck, S. Cheng, M. R. Fontecha, J. Li, J. C. Defesche, and J. J.P. Kastelein
Genetic Determinants of Cardiovascular Disease Risk in Familial Hypercholesterolemia
Arterioscler. Thromb. Vasc. Biol., July 1, 2005; 25(7): 1475 - 1481.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
H A W Neil, V Seagroatt, D J Betteridge, M P Cooper, P N Durrington, J P Miller, M Seed, R P Naoumova, G R Thompson, R Huxley, et al.
Established and emerging coronary risk factors in patients with heterozygous familial hypercholesterolaemia
Heart, December 1, 2004; 90(12): 1431 - 1437.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. H. Slyper
What Vascular Ultrasound Testing Has Revealed about Pediatric Atherogenesis, and a Potential Clinical Role for Ultrasound in Pediatric Risk Assessment
J. Clin. Endocrinol. Metab., July 1, 2004; 89(7): 3089 - 3095.
[Abstract] [Full Text] [PDF]

Home page
 J. Med. Genet.Home page
A Cenarro, M Artieda, S Castillo, P Mozas, G Reyes, D Tejedor, R Alonso, P Mata, M Pocovi, and F Civeira
A common variant in the ABCA1 gene is associated with a lower risk for premature coronary heart disease in familial hypercholesterolaemia
J. Med. Genet., March 1, 2003; 40(3): 163 - 168.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
F. J. Chaves, J. T. Real, A. B. Garcia-Garcia, M. Civera, M. E. Armengod, J. F. Ascaso, and R. Carmena
Genetic Diagnosis of Familial Hypercholesterolemia in a South European Outbreed Population: Influence of Low-Density Lipoprotein (LDL) Receptor Gene Mutations on Treatment Response to Simvastatin in Total, LDL, and High-Density Lipoprotein Cholesterol
J. Clin. Endocrinol. Metab., October 1, 2001; 86(10): 4926 - 4932.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
J.T Real, F.J Chaves, I Martinez-Uso, A.B Garcia-Garcia, J.F Ascaso, and R Carmena
Importance of HDL cholesterol levels and the total/ HDL cholesterol ratio as a risk factor for coronary heart disease in molecularly defined heterozygous familial hypercholesterolaemia
Eur. Heart J., March 2, 2001; 22(6): 465 - 471.
[Abstract] [PDF]

Home page
 HypertensionHome page
A. S. Wierzbicki, M. Lambert-Hammill, P. J. Lumb, and M. A. Crook
Renin-Angiotensin System Polymorphisms and Coronary Events in Familial Hypercholesterolemia
Hypertension, November 1, 2000; 36(5): 808 - 812.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
S. Bertolini, A. Cantafora, M. Averna, C. Cortese, C. Motti, S. Martini, G. Pes, A. Postiglione, C. Stefanutti, I. Blotta, et al.
Clinical Expression of Familial Hypercholesterolemia in Clusters of Mutations of the LDL Receptor Gene That Cause a Receptor-Defective or Receptor-Negative Phenotype
Arterioscler. Thromb. Vasc. Biol., September 1, 2000; 20 (9): e41 - e52.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
A. F. Vuorio, H. Gylling, H. Turtola, K. Kontula, P. Ketonen, and T. A. Miettinen
Stanol Ester Margarine Alone and With Simvastatin Lowers Serum Cholesterol in Families With Familial Hypercholesterolemia Caused by the FH-North Karelia Mutation
Arterioscler. Thromb. Vasc. Biol., February 1, 2000; 20(2): 500 - 506.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
H. H.-J. Schmidt, M. Stuhrmann, R. Shamburek, C. K. Schewe, M. Ebhardt, L. A. Zech, C. Büttner, M. Wendt, U. Beisiegel, H. B. Brewer, et al.
Delayed Low Density Lipoprotein (LDL) Catabolism Despite a Functional Intact LDL-Apolipoprotein B Particle and LDL-Receptor in a Subject with Clinical Homozygous Familial Hypercholesterolemia
J. Clin. Endocrinol. Metab., June 1, 1998; 83(6): 2167 - 2174.
[Abstract] [Full Text]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
A. F. Vuorio, H. Turtola, K.-M. Piilahti, P. Repo, T. Kanninen, and K. Kontula
Familial Hypercholesterolemia in the Finnish North Karelia : A Molecular, Clinical, and Genealogical Study
Arterioscler. Thromb. Vasc. Biol., November 1, 1997; 17(11): 3127 - 3138.
[Abstract] [Full Text]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
S. Tonstad, O. Joakimsen, E. Stensland-Bugge, T. P. Leren, L. Ose, D. Russell, and K. H. Bonaa
Risk Factors Related to Carotid Intima-Media Thickness and Plaque in Children With Familial Hypercholesterolemia and Control Subjects
Arterioscler. Thromb. Vasc. Biol., August 1, 1996; 16(8): 984 - 991.
[Abstract] [Full Text]